By Jason Napodano, CFA, And John Tucker, PhD
Ask a scientist or healthcare portfolio manager what the hot topics are in biotechnology today, and you will likely hear about cancer immunotherapy, stem cells, RNA interference and exon-skipping technologies. One subject they will probably not bring up is the reformulation of 20 year old drugs. Yet, Ireland-based Alkermes plc (NASDAQ:ALKS) has grown into a $4 billion company in part by doing exactly that.
As it's impossible to do justice to Alkermes' entire portfolio of products and drug delivery technologies in a single article, we'll focus instead on the company's efforts in the rapidly growing market for long-acting injectable (LAI) drugs for the treatment of schizophrenia. Below, we discuss how...
|FREE||SA PRO MEMBERS|
|IDEA GENERATOR||X||Exclusive access to 10 PRO ideas every day|
|INVESTING IDEAS LIBRARY||X||Exclusive access to PRO library of more than 15,000 ideas|
|SECTOR EXPERT NETWORK||X||Exclusive access to all sector experts for direct consultation|
|PERFORMANCE TRACKING||X||Track performance of all PRO stock ideas|
|PROFESSIONAL TOOLS||X||Professional Idea Filters to zero-in based on industry, market cap and more|